Phosphorylation and gene expression of p53 are not affected in human cells exposed to 2.1425 GHz band CW or W-CDMA modulated radiation allocated to mobile radio base stations

October 17, 2006 in Brain Tumor

H. Hirose 1 *, N. Sakuma 1, N. Kaji 1, T. Suhara 1, M. Sekijima 1, T. Nojima 2, J. Miyakoshi 3 1Research Division for Advanced Technology, Kashima Laboratory, Mitsubishi Chemical Safety Institute Ltd., Kamisu, Japan2Division of Electronics and Information Engineering, Graduate School of Hokkaido University, Sapporo, Japan3Department of Radiological Technology School of Health Sciences, [...]

Prognosis of cerebellar glioblastomas: correlation between prognosis and immunoreactivity for epidermal growth factor receptor compared with supratentorial glioblastomas

September 13, 2006 in Brain Tumor

Anticancer Res. 2006 Mar-Apr;26(2B):1351-7. * Saito T, * Hama S, * Kajiwara Y, * Sugiyama K, * Yamasaki F, * Arifin MT, * Arita K, * Kurisu K. Department of Neurosurgery, Hiroshima University, School of Medicine, Hiroshima, 734-8551, Japan. BACKGROUND: Cerebellar glioblastomas (GBM) are rare tumors whose clinicopathological characteristics are not well understood. PATIENTS AND [...]

cytoplasmic p16 appears to be an unfavorable prognostic indicator in high-grade astrocytomap

September 2, 2006 in Brain Tumor

 The negative consequences of the cytoplasmic localization of p16 in patients with high-grade astrocytomas, on their prognosis, was investigated.  p16 Expression was examined in 20 anaplastic astrocytoma and 42 glioblastoma patients by immunohistochemical analysis, and the relationship between both cytoplasmic and nuclear p16 expression and prognosis analyzed. The cytoplasmic expression of p16 statistically correlated with [...]

Recent developments in the use of chemotherapy in brain tumours

September 2, 2006 in Brain Tumor

Several recent studies have further clarified the role of chemotherapy in newly diagnosed anaplastic glioma. For newly diagnosed glioblastoma, combined daily radiotherapy with daily temozolomide followed by six cycles of adjuvant temozolomide improves overall survival. This benefit is especially observed in patients with a methylated promotor of the MGMT gene which encodes an alkyltransferase; this [...]